Anti-hIL-1β-IgG

Neutralizing monoclonal antibody against human interleukin 1 beta

Neutralizing monoclonal antibody against human IL-1β

Anti-hIL-1β-IgG is a monoclonal antibody (mAb) specific for human interleukin 1 beta (hIL-1β). It is produced in hybridomas and purified by affinity chromatography. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-1β.
IL-1β is a soluble pro-inflammatory cytokine that plays a critical role in the host response to infection and injury [1]. 

More details

Key features:

• A potent and specific neutralizing mAb against hIL-1β
• Provided azide-free
• No cross-reactivity with human IL-1α, murine IL-1α, or murine IL-1β
• Each lot is functionally tested

Reference:

1. Dinarello C., 2018. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 281(1): 8–27. 

Specifications

Target: Natural and recombinant human interleukin-1 beta (IL-1β)

Specificity: No cross-reactivity with human IL-1α, murine IL-1α, or murine IL-1β

Clone: 4H5

Isotype: Mouse IgG1, kappa

Control: Mouse IgG1 Control

Immunogen: Human IL-1β protein expressed in Swiss mice following DNA immunization

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Tested applications: Blocking & Neutralisation

Quality control:

• This product has been validated for neutralization.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Contents

• 3 x 100 μg purified anti-hIL-1β-IgG antibody, provided azide-free and lyophilized.

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

Reconstituted antibody is stable for 1 month at 4 °C and for 1 year at -20 °C.

 Avoid repeated freeze-thaw cycles.

Details

Interleukin-1 beta (IL-1β) is a secreted pro-inflammatory cytokine [1]. It participates in the generation of systemic and local responses to infection and injury [2]. IL-1β is produced by activated macrophages as a pro‑protein, which is cleaved by caspase 1, an enzyme that is activated within the inflammasome multiprotein complex [3].
The resulting mature IL-1β is secreted and binds to the IL-1RI receptor triggering the formation of the IL-1R1/IL-1R3/MyD88 complex and inducing MyD88‑mediated intracellular signaling. This leads to the activation of the transcription factor NK-κB signaling, and the JNK and p38 mitogen‑activated protein kinase pathways, which induce the expression of inflammatory cytokines and chemokines, such as IL-6 and IL-8 [4].
 

1. Dinarello C., 2018. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 281(1): 8-27.
2. Sims J. & Smith D., 2010. The IL-1 family: regulators of immunity. Nat Rev Immunol. 10(2):89-102.
3. O’Neill L., 2008. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226:10–18.
4. Weber A. et al., 2010. Interleukin-1 (IL-1) pathway. Sci Signal. 3(105):cm1.